Clinical Trials Logo

Filter by:
NCT ID: NCT06173414 Completed - Healthy Clinical Trials

Adaptive Optics ScanningLaser Ophthalmoscope Safety and Efficacy Clinical Trial

Start date: July 5, 2023
Phase:
Study type: Observational

This prospective, multicenter, single-group, target-value clinical trial was designed to evaluate the efficacy and safety of an Adaptive Optics ScanningLaser Ophthalmoscope(AOSLO) for ophthalmic examination.

NCT ID: NCT06173284 Recruiting - Dermatitis, Atopic Clinical Trials

Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis

Start date: January 22, 2024
Phase: Phase 3
Study type: Interventional

The primary objective of the study was to evaluate the efficacy of 611 in Chinese adults with moderate to severe atopic dermatitis.

NCT ID: NCT06173219 Recruiting - Clinical trials for Advanced Solid Tumor

Safety and Efficacy of Radiotherapy Combined With Immunotherapy for Advanced Malignant Tumors.

Start date: December 15, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to find a new radioimmunotherapy regimen for advanced malignancies with multiple metastatic after standard treatment failure/drug resistance. The main questions it aims to answer is: the safety and efficacy of the new regimen for advanced multiple metastatic solid tumors standard treatment failure/drug resistance, and explore the impact on immune function. Participants will receive the combination of radiotherapy and immunotherapy.

NCT ID: NCT06173115 Recruiting - Clinical trials for Severe Aortic Stenosis

Comparison of a Single Versus Double Perclose Technique for TAVR

Single
Start date: October 20, 2023
Phase: N/A
Study type: Interventional

Transcatheter aortic valve replacement (TAVR) has become widely recognized as a minimally invasive approach for aortic valve replacement in patients with severe aortic stenosis. It has been proven to be a safe and effective option for patients who are at low, intermediate, and prohibitive risk for surgical valve replacement. One of the critical components of procedural success in a transfemoral approach is access site management, as vascular complications strongly correlate with adverse outcomes. When major vascular complications occur, there are higher rates of major bleeding, transfusions, and renal failure requiring dialysis, as well as a significantly higher rate of 30-day and 1-year mortality. In recent years, a "preclosure" technique has emerged as a common vascular closure approach using a Perclose Proglide system (Abbott Vascular), in which sutures are deployed before dilating the arterial access site. This allows for arterial closure after dilation to sizing up to larger bore access sheaths that accommodate valve delivery systems. The sutures are subsequently harvested and tightened to close the large bore arteriotomy site at the end of the case. It has been demonstrated that the use of two Perclose devices, or double Perclose closure, is an effective closure technique with a low rate of vascular complications. A large number of TAVR centers have adopted this method for large-bore vascular closure. In the past, there have been few investigations comparing the utilization of a single Perclose device compared to a double Perclose technique. There are numerous theoretical advantages to the use of a single device, which include decreased procedural cost and procedural time. The investigation aimed to determine if there are clinical benefits as well using the single Perclose approach.

NCT ID: NCT06173076 Recruiting - Clinical trials for Autoimmune Encephalitis

A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis

Start date: May 18, 2022
Phase:
Study type: Observational

Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. It presents with acute or subacute onset of epileptic seizures, anterograde amnesia, behavior disturbances, sleep disorders and hyponatremia. In most patients with anti-LGI1 encephalitis, immunotherapy is successful in treating the encephalitis. However, relapses, chronic epilepsy, cognitive declines and psychiatric problems have been reported in some cases. So far, prospective studies to evaluate its clinical outcomes still remain limited. In this project, the investigators will use clinical features and advanced paraclinical examinations to prospectively investigate the clinical outcomes and the associated factors in patients with anti-LGI1 encephalitis.

NCT ID: NCT06173037 Not yet recruiting - Clinical trials for Primary Peritoneal Cancer

RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Start date: December 31, 2023
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the efficacy, safety, and pharmacokinetics of RC88 monotherapy in subjects with Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer (PROC).

NCT ID: NCT06173011 Recruiting - Tumor Clinical Trials

A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults

Start date: December 12, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to compare the pharmacokinetic and safety similarity of QL2107 with Keytruda® marketed in China and the United States in healthy male volunteers. Participants will receive a single injection of QL2107/ Keytruda® (China)/Keytruda® (US).Researchers will compare pharmacokinetic, safety, and immunogenic similarities between the three groups.

NCT ID: NCT06172998 Recruiting - Clinical trials for Obstructive Sleep Apnea

New Perspective on Exploring the Post-apneic BP Surge in Patients With OSA

Start date: April 1, 2022
Phase: Early Phase 1
Study type: Interventional

The nocturnal short-term BPV induced by sleep-breathing events is affected by many factors. The purpose of the study is as follows: (1) to explore the relationship between nocturnal short-term BPV and vascular endothelial function and sympathetic activity in patients with OSA respectively, (2) to explore which play the key role in BP fluctuation, (3) how to prevent the frequent BP fluctuation and arrive at a safe point.

NCT ID: NCT06172985 Active, not recruiting - Clinical trials for Coronary Heart Disease

A CCTA Image Assisted Triage Software for the Assessment of Patients With Suspected Coronary Artery Disease

Start date: May 9, 2023
Phase:
Study type: Observational

The goal of this clinical trail is to evaluate the effectiveness and accuracy of the CCTA image assisted triage software(DeepVessel® Cardisight, Keya Medical.) for the triage of patients with suspected coronary artery disease.

NCT ID: NCT06172855 Recruiting - Clinical trials for Premature Ejaculation

The Study on the Effectiveness and Safety of Electroacupuncture at ST36 in Treating Primary Premature Ejaculation

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

A pilot prospective single-arm cohort study on the Effectiveness and Safety of Electroacupuncture at ST36(Zusanli) in Treating Primary Premature Ejaculation